Core Viewpoint - Eddiecon Holdings (09860) announced the acquisition of 100% of the issued shares of Crown Bioscience International for a total purchase price of $204 million, which aligns with the company's strategy to expand its product portfolio and is expected to bring long-term strategic benefits [1][2]. Group 1: Acquisition Details - The buyer, Miramar Lifesciences Limited, a wholly-owned subsidiary of Eddiecon, entered into a share purchase agreement with the seller, JSR Life Sciences, LLC, regarding the acquisition of the target company [1]. - Upon completion of the transaction, Crown Bioscience International will become a wholly-owned subsidiary of Miramar Lifesciences Limited [1]. - The target company is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. Group 2: Company Operations - Eddiecon primarily provides Integrated Clinical Laboratory (ICL) services, along with medical testing, clinical trials, research services, health management, and pathology consultation services [1]. - The company focuses on research and development in core disease areas such as infectious diseases, women's health, solid tumors, perinatal and pediatric care, and hematology, covering multiple disciplines including internal medicine, pediatrics, obstetrics and gynecology, oncology, and neurology [1].

Core Viewpoint - The acquisition of Crown Bioscience International by Miramar Lifesciences Limited for a total purchase price of $204 million is expected to enhance the product portfolio of the company and provide long-term strategic benefits [1][2]. Company Overview - The target company, Crown Bioscience International, is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. - The company collaborates with biotechnology and pharmaceutical firms to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1]. Strategic Rationale - The board believes that the acquisition aligns with the group's development strategy to expand its product offerings [2]. - The acquisition is anticipated to bring long-term and strategic benefits to the company [2].

Group 1 - The core point of the article highlights the stock performance of Kingmed Diagnostics, which closed at 30.73 yuan on August 5, showing a slight decline of 0.09 yuan or 0.29% from the previous trading day [1] - On August 5, the stock opened at 30.85 yuan, reached a high of 31.38 yuan, and a low of 30.40 yuan, with an overall trading range of 3.18% and a trading volume of 84,190 hands, amounting to 260 million yuan [1] - Kingmed Diagnostics is a leading third-party medical testing institution in China, with its main business covering medical testing, pathological diagnosis, and research services, supported by a nationwide service network [1] Group 2 - At 13:01 on August 5, Kingmed Diagnostics experienced a rapid rebound, with a price increase of over 2% within 5 minutes, rising from 30.96 yuan to 31.21 yuan, with a transaction volume of 165 million yuan during that period [1] - Despite a net outflow of 7.02 million yuan in main funds by the end of the trading day, there was a cumulative net inflow of 53.83 million yuan over the past five trading days [1]